Scientists have used stem cells to create structures that resemble human embryos in the lab, in a first that has prompted calls for stricter regulation in the rapidly advancing field.

Several different labs around the world have released pre-print studies in the past seven days describing their research, which experts said should be treated with caution as the research has not yet been peer-reviewed.

The labs used different techniques to encourage human embryonic stem cells, which can become any type of cell, to self-assemble into a structure that resembles an embryo—without needing sperm, an egg or fertilization.

Immune checkpoint inhibitors (ICIs) have improved the landscape of cancer research over the past decade. These therapies, which target a patient’s own immune system aiming to make it stronger and more equipped to fight cancer, have provided novel and beneficial therapeutic options for patients with advanced and metastatic disease.

While ICIs can induce long-term responses and cures in patients with limited therapeutic options, they present significant challenges. First, different patients exhibit different levels of responsiveness to ICIs. So, when one patient achieves a cure, another with a similar type of cancer may remain non-responsive. While we don’t fully understand the reasons behind the disparate responsiveness of ICIs, this remains an active area of research globally. Second, ICI use can elicit toxicities known as immune-related adverse events (irAEs). In some patients irAEs can be managed and thus tolerable, especially given the anti-cancer effects. However, some patients experience severe irAEs that can significantly hinder the quality of life of cancer survivors. In some cases, serious and life-threatening irAEs can even require treatment discontinuation.

A pre-clinical study recently published in the Journal of Clinical and Experimental Cancer Research explores a potential regimen that may help confront both of these challenges. The researchers hypothesized that ICIs, if targeted directly to the lymph node (LN), could both enhance the anti-tumor response and reduce the associated irAEs.

Researchers have accidentally found that blocking caspase enzymes can make mouse immune responses more robust.

face_with_colon_three Year 2020

Cyanobacteria — colloquially also called blue-green algae — can produce oil from water and carbon dioxide with the help of light. This is shown by a recent study by the University of Bonn. The result is unexpected: Until now, it was believed that this ability was reserved for plants. It is possible that blue-green algae will now also become interesting as suppliers of feed or fuel, especially since they do not require arable land. The results have now been published in the journal PNAS.

What do rapeseed, avocado and olive tree have in common? They are all used by humans as producers of oil or fat. However, the ability to produce oil from water and carbon dioxide with the help of light is something that is essentially common to all plants, from unicellular algae to the giant sequoia trees. “We have now shown for the first time that cyanobacteria can do the same,” explains biologist Prof. Dr. Peter Dörmann from the Institute of Molecular Physiology and Biotechnology of Plants (IMBIO) at the University of Bonn. “This was a complete surprise, not only to us.”

Until now, experts had assumed that cyanobacteria lack this property. After all, they are actually bacteria, even if their trivial name “blue-green algae” suggests otherwise. They therefore differ considerably from plants in many respects: Cyanobacteria are closer related to the intestinal bacterium E. coli than to an olive tree. “There are indeed ancient reports in the literature that cyanobacteria can contain oil,” says Dörmann. “But these have never been verified.”

“I’d like to emphasize that these are neither embryos, nor are we trying to make embryos actually,” Dr. Jitesh Neupane, of the University of Cambridge’s Gurdon Institute, said.